Takeda’s EoE Drug Eohilia Gets First FDA Approval in US
Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension) for the...
Takeda’s TAK-861 Narcolepsy Phase 3 Trials Set for FY2024
Takeda has announced promising topline results from a Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R)...
Survey: Pharma Fears CRO Instability Amid Sector Mergers
Worldwide Clinical Trials has released a survey report on the perceptions of large and midsize contract research organizations (CROs)...
BMS’s Opdivo for Lung Cancer: US & EU Filings Accepted
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics Application (sBLA)...
AstraZeneca Grows US Cell Therapy Production Capacity
AstraZeneca has announced a $300 million investment in a new state-of-the-art facility in Rockville, Maryland, aimed at advancing its...
ICON Survey Stresses Combo Therapies in Obesity Care
ICON plc conducted an industry survey of over 100 professionals engaged in obesity-related clinical research, revealing expectations for the...
Gilead Evoke-01 Phase 3 Study: Critical Update Issued
Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study, which evaluated Trodelvy® (sacituzumab govitecan-hziy; SG) against docetaxel in...
8-Year Data: BMS Opdivo & Yervoy Outperform in RCC Survival
Bristol Myers Squibb (BMS) announced that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to show significant long-term...
Opdivo & Cabometyx Show 4-Year Benefits in RCC Trial
Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) has shown continued benefits in the first-line treatment of advanced renal cell...
Arcus & Gilead: Quemliclustat Regimens Show Hope in Pancreatic Cancer
Arcus Biosciences, Inc. announced promising overall survival data from the ARC-8 Phase 1b trial, co-developed with Gilead Sciences. The...